Imatinib mesylate: A designer drug.
Artigo
em Inglês
| IMSEAR
| ID: sea-94040
ABSTRACT
Molecularly targeted therapy is a novel approach in cancer treatment. Imatinib, a specific tyrosine kinase inhibitor, since its inception in 1990s, has become the first-line drug in management of chronic myelogenous leukemia (CML) chronic phase. It has also shown promising results in treatment of gastro-intestinal stromal tumors, clonal eosinophilic disorders and Philadelphia chromosome positive acute lymphatic leukemia. The efficacy of imatinib has geared up further research into development of designer drugs with molecular targets. This review gives a comprehensive description of the development, biology, utility, dosing, and limitations of imatinib mesylate.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Piperazinas
/
Pirimidinas
/
Cromossomo Filadélfia
/
Humanos
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Tumores do Estroma Gastrointestinal
/
Inibidores de Proteínas Quinases
/
Eosinofilia
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
Idioma:
Inglês
Ano de publicação:
2006
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS